ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY)’s stock price crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $13.77 and traded as high as $14.45. ASTELLAS PHARMA/ADR shares last traded at $14.42, with a volume of 23,471 shares.

The firm has a market cap of $28.50 billion, a price-to-earnings ratio of 13.84 and a beta of 0.72. The stock has a 50-day moving average of $13.77 and a 200-day moving average of $14.13.


Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers XTANDI and Eligard for the treatment of prostate cancer; Betanis/Myrbetriq/BETMIGA for overactive bladder (OAB) treatment; Vesicare forOAB treatment; Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia; VESOMNI for storage symptoms and voiding symptoms associated with benign prostatic hyperplasia; Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, animmunosuppressant; and Funguard/MYCAMINE, a candin-type antifungal agent.

Featured Article: How To Calculate Debt-to-Equity Ratio

Receive News & Ratings for ASTELLAS PHARMA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASTELLAS PHARMA/ADR and related companies with's FREE daily email newsletter.